Five patients were treated with mycophenolate mofetil for a median of 6 months. At 6-month follow up, three (60%) patients had responded to treatment. Of these, one (33%) was a responder and two (67%) were partial responders.
None of the patients on hydroxychloroquine experienced any adverse event, including no retinopathy. Three patients experienced an adverse event with the use of doxycycline. Two of these patients had a photosensitive reaction, while one experienced gastrointestinal symptoms. None of the patients reported an adverse reaction to mycophenolate mofetil.
In conclusion must be emphasized that Hydroxychloroquine is significantly effective in reducing signs and symptoms in patients with FFA and has its maximal benefit within the first 6 months of treatment.